Related Experiment Videos
[New antibody for breast cancer therapy. Interview by Brigitte Schalhorn]
Fortschritte Der Medizin
|August 6, 1998
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Statistical controversies in clinical research: statistical significance-too much of a good thing ….
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Annals of oncology : official journal of the European Society for Medical Oncology·2014
[Interventional therapy of BPH syndrome].
Fortschritte der Medizin·1999
[Practical conducting of blood pressure measuring. Important contributing factors and possibilities of errors].
Fortschritte der Medizin·1999
Mechanistic Basis and Therapeutic Potential of a Novel TXNIP Inhibitor in Diabetes Treatment.
Journal of medicinal chemistry·2026
Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.
Journal of medicinal chemistry·2026
Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study.
Frontiers in aging·2026